Skip to Content

Idiopathic Environmental Intolerance

(Multiple Chemical Sensitivity; Environmental Illness)


Donald W. Black

, MD, University of Iowa, Roy J. and Lucille A. Carver College of Medicine

Last full review/revision Jul 2020| Content last modified Jul 2020

Idiopathic environmental intolerance is characterized by recurrent, nonspecific symptoms attributed to low-level exposure to chemically unrelated substances commonly occurring in the environment or sometimes to hypersensitivity to electromagnetic fields. Symptoms are numerous, often involving multiple organ systems, but physical findings are unremarkable. Diagnosis is by exclusion. Treatment is psychologic support and avoidance of perceived triggers, although triggers rarely can be defined.

No universally accepted definition exists, but idiopathic environmental intolerance is generally defined as the development of multiple symptoms attributed to exposure to any number of identifiable or unidentifiable chemical substances (inhaled, touched, or ingested) or other exposures in the absence of clinically detectable organ dysfunction or related physical signs.

Etiology of Idiopathic Environmental Intolerance


Reported triggers for idiopathic environmental intolerance include

  • Alcohol and drugs
  • Caffeine and food additives
  • Carpet and furniture odors
  • Fuel odors and engine exhaust
  • Painting materials
  • Perfume and other scented products
  • Pesticides and herbicides
  • Mobile telecommunication devices


Immunologic and nonimmunologic theories have been proposed. They are hampered by lack of a consistent dose response to proposed causative substances; ie, symptoms may not be replicated after exposure to high levels of a substance that previously, at much lower levels, seemed to provoke a reaction. Similarly, consistent objective evidence of systemic inflammation, cytokine excess, or immune system activation in relation to symptoms is lacking. Many physicians consider the etiology to be psychologic, probably a form of somatic symptom disorder. Others suggest that the syndrome is a type of panic attack or agoraphobia.

Idiopathic environmental intolerance occurs in 40% of people with chronic fatigue syndrome and in 16% of people with fibromyalgia. Idiopathic environmental intolerance is more prevalent in women.

Although measurable biologic abnormalities (eg, decreased levels of B cells, elevated levels of IgE) are rare, some patients have such abnormalities. However, these abnormalities appear without a consistent pattern, their significance is uncertain, and testing for these abnormalities to establish an immunologic basis for the disorder should be discouraged.

Symptoms and Signs

Symptoms (eg, palpitations, chest pain, sweating, shortness of breath, fatigue, flushing, dizziness, nausea, choking, trembling, numbness, coughing, hoarseness, difficulty concentrating) are numerous and usually involve more than one organ system. Most patients present with a long list of suspected agents, self-identified or identified by a physician during previous testing. Such patients often go to great lengths to avoid these agents by changing residence and employment, avoiding foods containing “chemicals,” sometimes wearing masks in public, or avoiding public settings altogether. Physical examination is characteristically unremarkable.


  • Exclusion of other causes

Diagnosis initially involves exclusion of known disorders with similar manifestations:

Atopic disorders are excluded based on a typical clinical history, skin-prick testing, serum assays of specific IgE, or all 3. Consultation with an allergy specialist may be helpful. Building-related illnesses, in which many people who spend time in the same building develop symptoms, should be considered.

If symptoms and signs are not strongly suggestive of a "connective tissue" or systemic autoimmune rheumatologic disorder (eg, joint, skin and/or mucous membrane manifestations), testing for a wide range of autoantibodies (eg, antinuclear antibodies [ANA], rheumatoid factor, extractable nuclear antigens [ENA]) should be avoided. In such cases, pretest probability is low and false-positive results are far more likely than true-positive results; a weakly positive ANA is present in about 20% of the population.


  • Sometimes avoiding suspected triggers
  • Psychologic treatments

Despite an uncertain cause-and-effect relationship, treatment is sometimes aimed at avoiding the suspected precipitating agents, which may be difficult because many are ubiquitous. However, social isolation and costly and highly disruptive avoidance behaviors should be discouraged. A supportive relationship with a primary care physician who offers reassurance and protects patients from unnecessary tests and procedures is helpful.

Psychologic evaluation and intervention may help, but characteristically many patients resist this approach. However, the point of this approach is not to convince patients that the cause is psychologic but rather to help them cope with their symptoms and improve quality of life (1). Useful techniques include psychologic desensitization (often as part of cognitive-behavioral therapy) (1) and graded exposure (see Specific Phobic Disorders : Treatment). Psychoactive drugs can be helpful if targeted toward coexisting psychiatric disorders (eg, major depression, panic disorder).

Treatment reference

  • Hauge CR, Rasmussen A, Piet J, et al: Mindfulness-based cognitive therapy (MBCT) for multiple chemical sensitivity (MCS): Results from a randomized controlled trial with 1 year follow-up. J Psychosom Res 79(6):628-634, 2015. doi: 10.1016/jpsychores.2015.06.010

Key Points

  • Based on current evidence, idiopathic environmental intolerance cannot be explained by non-psychologic factors.
  • For diagnosis, exclude disorders that can have similar manifestations (eg, allergic disorders) and consider building-related illnesses.
  • Test for immunologic abnormalities only if indicated by objective clinical findings.
  • Encourage psychologic therapies such as graded exposure and drug treatment of coexisting psychiatric disorders.

Copyright © 2022 Merck & Co., Inc., known as MSD outside of the US, Kenilworth, New Jersey, USA. All rights reserved. Merck Manual Disclaimer